PON-dering differences in HDL function in coronary artery disease

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

HDL cholesterol activates endothelial cell production of the atheroprotective signaling molecule NO, and it promotes endothelial repair. In this issue of the JCI, Besler et al. provide new data indicating that HDL from stable coronary artery disease (CAD) or acute coronary syndrome patients inhibits rather than stimulates endothelial NO synthesis and endothelial repair. This may be related to decreased HDL-associated paraoxonase 1 (PON1) activity. These observations support the concept that the cardiovascular impact of HDL is not simply related to its abundance, and the translation of the present findings to prospective studies of CAD risk and to evaluations of HDL-targeted therapeutics is a logical future goal.

Original languageEnglish (US)
Pages (from-to)2545-2548
Number of pages4
JournalJournal of Clinical Investigation
Volume121
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Coronary Artery Disease
Aryldialkylphosphatase
Acute Coronary Syndrome
HDL Cholesterol
Endothelial Cells
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PON-dering differences in HDL function in coronary artery disease. / Mineo, Chieko; Shaul, Philip W.

In: Journal of Clinical Investigation, Vol. 121, No. 7, 07.2011, p. 2545-2548.

Research output: Contribution to journalArticle

@article{736990a580074878bdcf31e91b101ee1,
title = "PON-dering differences in HDL function in coronary artery disease",
abstract = "HDL cholesterol activates endothelial cell production of the atheroprotective signaling molecule NO, and it promotes endothelial repair. In this issue of the JCI, Besler et al. provide new data indicating that HDL from stable coronary artery disease (CAD) or acute coronary syndrome patients inhibits rather than stimulates endothelial NO synthesis and endothelial repair. This may be related to decreased HDL-associated paraoxonase 1 (PON1) activity. These observations support the concept that the cardiovascular impact of HDL is not simply related to its abundance, and the translation of the present findings to prospective studies of CAD risk and to evaluations of HDL-targeted therapeutics is a logical future goal.",
author = "Chieko Mineo and Shaul, {Philip W.}",
year = "2011",
month = "7",
doi = "10.1172/JCI57671",
language = "English (US)",
volume = "121",
pages = "2545--2548",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - PON-dering differences in HDL function in coronary artery disease

AU - Mineo, Chieko

AU - Shaul, Philip W.

PY - 2011/7

Y1 - 2011/7

N2 - HDL cholesterol activates endothelial cell production of the atheroprotective signaling molecule NO, and it promotes endothelial repair. In this issue of the JCI, Besler et al. provide new data indicating that HDL from stable coronary artery disease (CAD) or acute coronary syndrome patients inhibits rather than stimulates endothelial NO synthesis and endothelial repair. This may be related to decreased HDL-associated paraoxonase 1 (PON1) activity. These observations support the concept that the cardiovascular impact of HDL is not simply related to its abundance, and the translation of the present findings to prospective studies of CAD risk and to evaluations of HDL-targeted therapeutics is a logical future goal.

AB - HDL cholesterol activates endothelial cell production of the atheroprotective signaling molecule NO, and it promotes endothelial repair. In this issue of the JCI, Besler et al. provide new data indicating that HDL from stable coronary artery disease (CAD) or acute coronary syndrome patients inhibits rather than stimulates endothelial NO synthesis and endothelial repair. This may be related to decreased HDL-associated paraoxonase 1 (PON1) activity. These observations support the concept that the cardiovascular impact of HDL is not simply related to its abundance, and the translation of the present findings to prospective studies of CAD risk and to evaluations of HDL-targeted therapeutics is a logical future goal.

UR - http://www.scopus.com/inward/record.url?scp=79960028404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960028404&partnerID=8YFLogxK

U2 - 10.1172/JCI57671

DO - 10.1172/JCI57671

M3 - Article

C2 - 21701074

AN - SCOPUS:79960028404

VL - 121

SP - 2545

EP - 2548

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -